Corixa
Date | Investors | Amount | Round |
---|---|---|---|
$15.0m | Series A | ||
N/A | - | ||
N/A | N/A | IPO | |
$233m Valuation: $233m | Acquisition | ||
Total Funding | $15.0m |
Recent News about Corixa
EditCoulterPharm is a pioneering biotechnology company specializing in the development of immunotherapeutics aimed at treating and preventing autoimmune diseases, cancer, and infectious diseases. The company leverages advanced technology platforms to understand and direct the immune system, creating targeted therapies that address critical health challenges. CoulterPharm serves a diverse range of clients, including healthcare providers, research institutions, and pharmaceutical companies, operating primarily in the biotech and pharmaceutical markets. The business model revolves around the research, development, and commercialization of its proprietary therapeutic products. Revenue is generated through product sales, research grants, and strategic partnerships with other industry players. CoulterPharm's commitment to innovation and scientific excellence positions it as a leader in the field of immunotherapy.
Keywords: immunotherapeutics, autoimmune diseases, cancer, infectious diseases, immune system, biotechnology, pharmaceutical, research, innovation, healthcare.